IBDEI0Z9 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15916,0)
 ;;=L57.0^^61^765^13
 ;;^UTILITY(U,$J,358.3,15916,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15916,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,15916,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,15916,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,15917,0)
 ;;=L60.0^^61^765^164
 ;;^UTILITY(U,$J,358.3,15917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15917,1,3,0)
 ;;=3^Ingrowing Nail
 ;;^UTILITY(U,$J,358.3,15917,1,4,0)
 ;;=4^L60.0
 ;;^UTILITY(U,$J,358.3,15917,2)
 ;;=^5009234
 ;;^UTILITY(U,$J,358.3,15918,0)
 ;;=L60.1^^61^765^272
 ;;^UTILITY(U,$J,358.3,15918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15918,1,3,0)
 ;;=3^Onycholysis
 ;;^UTILITY(U,$J,358.3,15918,1,4,0)
 ;;=4^L60.1
 ;;^UTILITY(U,$J,358.3,15918,2)
 ;;=^186837
 ;;^UTILITY(U,$J,358.3,15919,0)
 ;;=L60.2^^61^765^271
 ;;^UTILITY(U,$J,358.3,15919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15919,1,3,0)
 ;;=3^Onychogryphosis
 ;;^UTILITY(U,$J,358.3,15919,1,4,0)
 ;;=4^L60.2
 ;;^UTILITY(U,$J,358.3,15919,2)
 ;;=^5009235
 ;;^UTILITY(U,$J,358.3,15920,0)
 ;;=L60.3^^61^765^176
 ;;^UTILITY(U,$J,358.3,15920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15920,1,3,0)
 ;;=3^Nail Dystrophy
 ;;^UTILITY(U,$J,358.3,15920,1,4,0)
 ;;=4^L60.3
 ;;^UTILITY(U,$J,358.3,15920,2)
 ;;=^5009236
 ;;^UTILITY(U,$J,358.3,15921,0)
 ;;=L60.4^^61^765^89
 ;;^UTILITY(U,$J,358.3,15921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15921,1,3,0)
 ;;=3^Beau's Lines
 ;;^UTILITY(U,$J,358.3,15921,1,4,0)
 ;;=4^L60.4
 ;;^UTILITY(U,$J,358.3,15921,2)
 ;;=^5009237
 ;;^UTILITY(U,$J,358.3,15922,0)
 ;;=L60.5^^61^765^330
 ;;^UTILITY(U,$J,358.3,15922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15922,1,3,0)
 ;;=3^Yellow Nail Syndrome
 ;;^UTILITY(U,$J,358.3,15922,1,4,0)
 ;;=4^L60.5
 ;;^UTILITY(U,$J,358.3,15922,2)
 ;;=^5009238
 ;;^UTILITY(U,$J,358.3,15923,0)
 ;;=L60.8^^61^765^174
 ;;^UTILITY(U,$J,358.3,15923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15923,1,3,0)
 ;;=3^Nail Disorders NEC
 ;;^UTILITY(U,$J,358.3,15923,1,4,0)
 ;;=4^L60.8
 ;;^UTILITY(U,$J,358.3,15923,2)
 ;;=^5009239
 ;;^UTILITY(U,$J,358.3,15924,0)
 ;;=L62.^^61^765^175
 ;;^UTILITY(U,$J,358.3,15924,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15924,1,3,0)
 ;;=3^Nail Disorders in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,15924,1,4,0)
 ;;=4^L62.
 ;;^UTILITY(U,$J,358.3,15924,2)
 ;;=^5009241
 ;;^UTILITY(U,$J,358.3,15925,0)
 ;;=L64.9^^61^765^34
 ;;^UTILITY(U,$J,358.3,15925,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15925,1,3,0)
 ;;=3^Androgenic Alopecia,Unspec
 ;;^UTILITY(U,$J,358.3,15925,1,4,0)
 ;;=4^L64.9
 ;;^UTILITY(U,$J,358.3,15925,2)
 ;;=^5009249
 ;;^UTILITY(U,$J,358.3,15926,0)
 ;;=L65.9^^61^765^269
 ;;^UTILITY(U,$J,358.3,15926,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15926,1,3,0)
 ;;=3^Nonscarring Hair Loss,Unspec
 ;;^UTILITY(U,$J,358.3,15926,1,4,0)
 ;;=4^L65.9
 ;;^UTILITY(U,$J,358.3,15926,2)
 ;;=^5009252
 ;;^UTILITY(U,$J,358.3,15927,0)
 ;;=L70.0^^61^765^7
 ;;^UTILITY(U,$J,358.3,15927,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15927,1,3,0)
 ;;=3^Acne Vulgaris
 ;;^UTILITY(U,$J,358.3,15927,1,4,0)
 ;;=4^L70.0
 ;;^UTILITY(U,$J,358.3,15927,2)
 ;;=^5009268
 ;;^UTILITY(U,$J,358.3,15928,0)
 ;;=L70.1^^61^765^2
 ;;^UTILITY(U,$J,358.3,15928,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15928,1,3,0)
 ;;=3^Acne Conglobata
 ;;^UTILITY(U,$J,358.3,15928,1,4,0)
 ;;=4^L70.1
 ;;^UTILITY(U,$J,358.3,15928,2)
 ;;=^5009269
